Canada's Only Single-Dose Cholera Vaccine Available Nationwide
16 sept. 2024 08h00 HE
|
Bavarian Nordic A/S
Bavarian Nordic announces availability of VAXCHORA, Canada's only single-dose cholera vaccine for travelers (age 2 to 64) to cholera-affected countries.
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
16 sept. 2024 07h00 HE
|
Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
09 sept. 2024 08h00 HE
|
Evaxion Biotech
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16...
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
09 sept. 2024 07h00 HE
|
Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President
20 août 2024 07h00 HE
|
Sabin Vaccine Institute
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Virologist and vaccine development leader Kelly Warfield has...
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
19 août 2024 17h10 HE
|
Emergent BioSolutions
Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission50,000 doses of ACAM2000®, (Smallpox...
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
15 juil. 2024 10h29 HE
|
Sabin Vaccine Institute
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month. WASHINGTON, July 15, 2024 (GLOBE NEWSWIRE) -- Sabin Vaccine...
Misleading COVID-19 headlines from mainstream sources did more harm on Facebook than fake news
30 mai 2024 15h01 HE
|
MIT Sloan School of Management
Cambridge, MA, May 30, 2024 (GLOBE NEWSWIRE) -- Since the rollout of the COVID-19 vaccine in 2021, fake news on social media has been widely blamed for low vaccine uptake in the United States — but...
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
09 mai 2024 16h05 HE
|
HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May ...
Global Impact, on behalf of the Advancing Health Online Initiative (AHO) and Gavi, The Vaccine Alliance, invests $12 million through the VaxSocial Initiative to implement innovative social media interventions to build vaccine confidence
01 mai 2024 10h34 HE
|
Global Impact
Geneva, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- Global Impact, as fiscal sponsor for the VaxSocial Initiative, is pleased to announce the selection of seven organizations that will receive...